Abstract
Antibiotic resistance is a global challenge likely to cost trillions of dollars in excess costs in the health system and more importantly, millions of lives every year. A major driver of resistance is the absence of susceptibility testing at the time a healthcare worker needs to prescribe an antimicrobial. The effect is that many prescriptions are unintentionally wasted and expose mutable organisms to antibiotics increasing the risk of resistance emerging. Often simplistic solutions are applied to this growing issue, such as a naïve drive to increase the speed of drug susceptibility testing. This puts a spotlight on a technological solution and there is a multiplicity of such candidate DST tests in development. Yet, if we do not define the necessary information and the speed at which it needs to be available in the clinical decision-making progress as well as the necessary integration into clinical pathways, then little progress will be made. In this chapter, we place the technological challenge in a clinical and systems context. Further, we will review the landscape of some promising technologies that are emerging and attempt to place them in the clinic where they will have to succeed.
Original language | English |
---|---|
Pages (from-to) | 129-143 |
Number of pages | 15 |
Journal | Methods in Molecular Biology |
Volume | 2833 |
DOIs | |
Publication status | Published - 2024 |
Keywords
- Anti-Bacterial Agents/pharmacology
- Microbial Sensitivity Tests/methods
- Humans
- Drug Resistance, Bacterial/drug effects
- Bacteria/drug effects